In conclusion, we have discovered a selective and potent small molecule inhibitor of the NLRP3 inflammasome and demonstrated its efficacy in murine models of CAPS and neutrophilic airway inflammation. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.